PriceTargets.com logo

PROCEPT BioRobotics - PRCT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $89.50
  • Forecasted Upside: -3.45%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$92.70 As of 11/20/2024 01:00 AM ET
▼ -0.87 (-0.93%)

This chart shows the closing price for PRCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PROCEPT BioRobotics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRCT

Analyst Price Target is $89.50
▼ -3.45% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for PROCEPT BioRobotics in the last 3 months. The average price target is $89.50, with a high forecast of $105.00 and a low forecast of $69.00. The average price target represents a -3.45% upside from the last price of $92.70.

This chart shows the closing price for PRCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in PROCEPT BioRobotics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Jefferies Financial GroupInitiated CoverageHold$95.00
10/30/2024Truist FinancialReiterated RatingBuy ➝ Buy$95.00 ➝ $105.00
10/8/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$75.00 ➝ $75.00
9/16/2024TD CowenBoost TargetBuy ➝ Buy$75.00 ➝ $99.00
9/3/2024Truist FinancialBoost TargetBuy ➝ Buy$74.00 ➝ $95.00
8/22/2024Bank of AmericaBoost TargetBuy ➝ Buy$80.00 ➝ $94.00
8/2/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$67.00 ➝ $69.00
8/2/2024Truist FinancialReiterated RatingBuy ➝ Buy$79.00 ➝ $74.00
7/16/2024Truist FinancialBoost TargetBuy ➝ Buy$72.00 ➝ $79.00
5/6/2024TD CowenBoost TargetBuy ➝ Buy$65.00 ➝ $75.00
5/6/2024Piper SandlerBoost TargetOverweight ➝ Overweight$67.00 ➝ $75.00
5/2/2024Truist FinancialBoost TargetBuy ➝ Buy$63.00 ➝ $72.00
2/28/2024Truist FinancialBoost TargetBuy ➝ Buy$55.00 ➝ $58.00
1/9/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$44.00 ➝ $47.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$48.00 ➝ $50.00
12/13/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$40.00 ➝ $44.00
10/16/2023Leerink PartnrsReiterated RatingOutperform
10/16/2023Leerink PartnersInitiated CoverageOutperform$37.00
9/13/2023Truist FinancialReiterated RatingBuy ➝ Buy$49.00
8/11/2023Piper SandlerInitiated CoverageOverweight$42.00
5/31/2023William BlairInitiated CoverageOutperform
4/28/2023Truist FinancialLower Target$54.00 ➝ $49.00
4/28/2023Bank of AmericaLower Target$52.00 ➝ $44.00
1/31/2023Truist FinancialLower TargetBuy$58.00 ➝ $55.00
1/12/2023Wells Fargo & CompanyLower TargetOverweight$52.00 ➝ $43.00
12/12/2022Wells Fargo & CompanyBoost TargetOverweight$49.00 ➝ $52.00
11/14/2022Truist FinancialBoost Target$56.00 ➝ $58.00
11/4/2022The Goldman Sachs GroupBoost TargetNeutral$39.00 ➝ $44.00
11/4/2022KeyCorpBoost TargetOverweight$47.00 ➝ $48.00
10/31/2022BTIG ResearchInitiated CoverageNeutral
10/25/2022Truist FinancialInitiated CoverageBuy$58.00
9/2/2022Wells Fargo & CompanyInitiated CoverageOverweight$49.00
7/15/2022KeyCorpInitiated CoverageOverweight$47.00
6/23/2022B. RileyInitiated CoverageBuy$53.00
3/9/2022Bank of AmericaLower TargetBuy$48.00 ➝ $42.00
3/9/2022GuggenheimLower Target$55.00 ➝ $40.00
3/9/2022Leerink PartnersBoost TargetOutperform$25.00 ➝ $30.00
11/5/2021Leerink PartnersBoost TargetOutperform$46.00 ➝ $55.00
10/11/2021Bank of AmericaInitiated CoverageBuy$48.00
10/11/2021Leerink PartnersInitiated CoverageOutperform$46.00
10/11/2021GuggenheimInitiated CoverageBuy$45.00
10/11/2021CowenInitiated CoverageOutperform$50.00
10/11/2021The Goldman Sachs GroupInitiated CoverageNeutral$37.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 12 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 13 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 11 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 17 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 14 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 19 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 19 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

PROCEPT BioRobotics logo
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Read More

Today's Range

Now: $92.70
Low: $91.47
High: $94.34

50 Day Range

MA: $81.88
Low: $66.83
High: $99.07

52 Week Range

Now: $92.70
Low: $31.57
High: $103.81

Volume

433,585 shs

Average Volume

659,946 shs

Market Capitalization

$4.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of PROCEPT BioRobotics?

The following Wall Street sell-side analysts have issued stock ratings on PROCEPT BioRobotics in the last year: Bank of America Co., Jefferies Financial Group Inc., Piper Sandler, TD Cowen, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for PRCT.

What is the current price target for PROCEPT BioRobotics?

0 Wall Street analysts have set twelve-month price targets for PROCEPT BioRobotics in the last year. Their average twelve-month price target is $89.50, suggesting a possible downside of 3.5%. Truist Financial Co. has the highest price target set, predicting PRCT will reach $105.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $69.00 for PROCEPT BioRobotics in the next year.
View the latest price targets for PRCT.

What is the current consensus analyst rating for PROCEPT BioRobotics?

PROCEPT BioRobotics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PRCT.

What other companies compete with PROCEPT BioRobotics?

Other companies that are similar to PROCEPT BioRobotics include Teleflex, Atrion, Nano-X Imaging, Inogen and Bionano Genomics. Learn More about companies similar to PROCEPT BioRobotics.

How do I contact PROCEPT BioRobotics' investor relations team?

PROCEPT BioRobotics' physical mailing address is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. The company's listed phone number is 650-232-7200 and its investor relations email address is [email protected]. The official website for PROCEPT BioRobotics is www.procept-biorobotics.com. Learn More about contacing PROCEPT BioRobotics investor relations.